Navigation Links
Blindness can be stopped with drug for acne treatment

Stargardt's macular degeneration, also called juvenile macular degeneration, is an inherited disease which affects one in 10,000 people. This condition results from a defect in the ABCR gene, which is responsible for coding for a protein that removes all-trans-retinaldehyde, a vision byproduct, from retinal rods and cones. Rods and cones are supported by retinal-pigmented epithelium (RPE), a layer of cells near the retina. The accumulation of toxic pigments, or lipofuscin// results in the deterioration of the RPE leading to loss of rods and cones and subsequent central vision loss.

Researchers from the University of California, Los Angeles, have now found that Accutane, an acne treatment drug, stops the accumulation of lipofuscin in the eyes of mice with Stargardt's macular degeneration. Upon examination of the mice after two months of treatment with Accutane, the side effect of which includes night blindness, the researchers found no accumulation of toxins in the eyes. Gabriel Travis, M.D., suggested that the similarity of the mouse model with humans with Stargardt's makes it likely that Accutane will suppress lipofuscin from accumulating in Stargardt's patients.


'"/>




Page: 1

Related medicine news :

1. Smoking Linked to Blindness
2. Blindness may be genetic by nature
3. Enzyme Responsible For Congenital Blindness
4. Millions Of Diabetic And Glaucoma Patients Risk Blindness
5. Avastin, anti-Cancer Drug leads to Blindness and Other Complications
6. Genes That Were Responsible For The Cause Of Blindness Identified
7. Investigations Reveal That Infections Due To Contact lens Could Cause Blindness
8. Research into Blindness Cure Goes Digital
9. River Blindness Incidence Reduced With Effective Treatment
10. Blindness And Trachoma
11. Blindness cases in China on the rise
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:4/25/2017)... ... April 25, 2017 , ... ... animal healthcare products, is introducing Flexadin UCII, part of the EQUISTRO line, at ... and joint health in horses at the immunologic level. , The scientifically-developed Flexadin ...
(Date:4/24/2017)... ... 24, 2017 , ... Michael Vick announced his retirement earlier this year from ... overall number one pick in the 2001 NFL Draft, to the Atlanta Falcons, made ... the most career rushing yards by a quarterback (6,109) and the most rushing yards ...
(Date:4/24/2017)... ... April 24, 2017 , ... NEPC Director Kevin Welner has ... Research Award. The award honors scholars exemplary in their capacity to communicate important ... has demonstrated the capacity to deepen the public’s understanding and appreciation of the ...
(Date:4/24/2017)... ... April 24, 2017 , ... Sean Fay is the ... Bag, Sonicare Toothbrush, Juiceman Juicer, and the George Foreman Grill (which sold more than ... marketer in the last 25 years. , Now, due to changes in the broadcast ...
(Date:4/24/2017)... Virginia (PRWEB) , ... April 24, 2017 , ... ... announced that they are seeking public support to bring their novel lifesaving device ... appearance, wearable device packed with medical-grade sensors, specially designed to read a child’s ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... 20, 2017  RXi Pharmaceuticals Corporation (NASDAQ: RXII), ... address significant unmet medical needs, today announced that ... consumer product development program, based on its proprietary ... Investigative Dermatology (SID) 76 th Annual Meeting.  ... the sciences relevant to skin health and disease ...
(Date:4/20/2017)... R.I. , April 20, 2017  CVS ... CVS), today unveiled a new store design to ... assortment of healthier food, health-focused products and expanded ... store to help customers discover new offerings. Together ... the next evolution of the customer experience at ...
(Date:4/20/2017)... 2017  AbbVie (NYSE: ABBV), a global biopharmaceutical ... chronic hepatitis C virus (HCV) infected patients with ... compensated cirrhosis (Child-Pugh A) achieved sustained virologic response ... its investigational, pan-genotypic regimen of glecaprevir/pibrentasvir (G/P). These ... 12 weeks of G/P treatment without ribavirin. Patients ...
Breaking Medicine Technology: